BR0008228A - Composições de n-benzoil estaurosporinaespontaneamente dispersìveis - Google Patents

Composições de n-benzoil estaurosporinaespontaneamente dispersìveis

Info

Publication number
BR0008228A
BR0008228A BR0008228-7A BR0008228A BR0008228A BR 0008228 A BR0008228 A BR 0008228A BR 0008228 A BR0008228 A BR 0008228A BR 0008228 A BR0008228 A BR 0008228A
Authority
BR
Brazil
Prior art keywords
compositions
spontaneously dispersible
benzoyl staurosporine
benzoyl
spontaneously
Prior art date
Application number
BR0008228-7A
Other languages
English (en)
Other versions
BRPI0008228B8 (pt
BRPI0008228B1 (pt
Inventor
Graham Paul Matthews
Barbara Haeberlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0008228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0008228A publication Critical patent/BR0008228A/pt
Publication of BRPI0008228B1 publication Critical patent/BRPI0008228B1/pt
Publication of BRPI0008228B8 publication Critical patent/BRPI0008228B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES DE N-BENZOILESTAUROSPORINA ESPONTANEAMENTE DISPERSìVEIS".Composições de N-benzoil estaurosporina espontaneamentedispersíveis são discutidas para administração oral tendo níveiselevados de biodisponibilidade e variabilidade reduzida dos níveisde biodisponibilidade da N-benzoil estaurosporina, bem como seupreparo e uso em tratamento médico.
BRPI0008228A 1999-02-16 2000-02-14 composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes BRPI0008228B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Publications (3)

Publication Number Publication Date
BR0008228A true BR0008228A (pt) 2001-10-30
BRPI0008228B1 BRPI0008228B1 (pt) 2016-08-23
BRPI0008228B8 BRPI0008228B8 (pt) 2021-05-25

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0008228A BRPI0008228B8 (pt) 1999-02-16 2000-02-14 composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes

Country Status (34)

Country Link
US (3) US20020061873A1 (pt)
EP (1) EP1152750B1 (pt)
JP (2) JP5057610B2 (pt)
KR (2) KR100880859B1 (pt)
CN (1) CN100367930C (pt)
AR (2) AR022589A1 (pt)
AT (1) ATE430554T1 (pt)
AU (1) AU765776B2 (pt)
BR (1) BRPI0008228B8 (pt)
CA (1) CA2362277C (pt)
CL (1) CL2009001682A1 (pt)
CZ (1) CZ303979B6 (pt)
DE (1) DE60042151D1 (pt)
DK (1) DK1152750T3 (pt)
EC (1) ECSP083351A (pt)
ES (1) ES2326783T3 (pt)
GB (1) GB9903547D0 (pt)
HK (1) HK1045807B (pt)
HU (1) HUP0105364A3 (pt)
ID (1) ID30504A (pt)
IL (3) IL144512A0 (pt)
MY (1) MY128362A (pt)
NO (1) NO331232B1 (pt)
NZ (1) NZ513529A (pt)
PE (1) PE20001499A1 (pt)
PL (1) PL198330B1 (pt)
PT (1) PT1152750E (pt)
RU (1) RU2266121C2 (pt)
SI (1) SI1152750T1 (pt)
SK (1) SK286967B6 (pt)
TR (1) TR200102385T2 (pt)
TW (1) TWI240636B (pt)
WO (1) WO2000048571A1 (pt)
ZA (1) ZA200106677B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
DK1372611T3 (da) * 2001-03-26 2006-09-18 Novartis Ag Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer
KR20030094415A (ko) 2001-05-16 2003-12-11 노파르티스 아게 Ν-｛5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐｝-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를포함하는 배합물
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
MX2012007229A (es) * 2009-12-22 2012-07-30 Leo Pharma As Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos.
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2013042069A1 (en) 2011-09-22 2013-03-28 Ariel-University Research And Development Company, Ltd. Emulsions and methods of making emulsions
KR20190032265A (ko) * 2015-12-09 2019-03-27 포스파제닉스 리미티드 약제학적 제형
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
US20190330260A1 (en) 2016-12-21 2019-10-31 Avecho Biotechnology Limited Process
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (pt) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
ES2136620T3 (es) 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
IL115742A (en) 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
AU4491697A (en) 1996-09-27 1998-04-17 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
SG115386A1 (en) * 1997-01-30 2005-10-28 Novartis Ag Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil
NZ502569A (en) 1997-07-29 2002-05-31 Upjohn Co Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4
JP5005847B2 (ja) 1997-07-29 2012-08-22 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 親油性化合物用の自己乳化性処方
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
PL198330B1 (pl) 2008-06-30
DE60042151D1 (de) 2009-06-18
SI1152750T1 (sl) 2009-10-31
PT1152750E (pt) 2009-08-07
BRPI0008228B8 (pt) 2021-05-25
TWI240636B (en) 2005-10-01
US20140056974A1 (en) 2014-02-27
HK1045807B (zh) 2008-12-05
RU2266121C2 (ru) 2005-12-20
SK11722001A3 (sk) 2001-12-03
BRPI0008228B1 (pt) 2016-08-23
HUP0105364A2 (hu) 2002-05-29
NO331232B1 (no) 2011-11-07
US8722664B2 (en) 2014-05-13
AU765776B2 (en) 2003-10-02
KR20010093281A (ko) 2001-10-27
ATE430554T1 (de) 2009-05-15
ECSP083351A (es) 2008-08-29
JP2002537242A (ja) 2002-11-05
ES2326783T3 (es) 2009-10-20
NZ513529A (en) 2003-10-31
CA2362277C (en) 2010-03-30
US8575147B2 (en) 2013-11-05
IL144512A0 (en) 2002-05-23
IL144512A (en) 2011-03-31
SK286967B6 (sk) 2009-08-06
EP1152750B1 (en) 2009-05-06
MY128362A (en) 2007-01-31
US20020061873A1 (en) 2002-05-23
CZ303979B6 (cs) 2013-07-31
EP1152750A1 (en) 2001-11-14
CZ20012931A3 (cs) 2001-11-14
HK1045807A1 (en) 2002-12-13
US20080070897A1 (en) 2008-03-20
AU3154200A (en) 2000-09-04
CN100367930C (zh) 2008-02-13
NO20013964D0 (no) 2001-08-15
AR022589A1 (es) 2002-09-04
KR100880859B1 (ko) 2009-01-30
CA2362277A1 (en) 2000-08-24
CL2009001682A1 (es) 2010-07-23
ZA200106677B (en) 2003-01-14
JP5057610B2 (ja) 2012-10-24
JP2012111763A (ja) 2012-06-14
WO2000048571A1 (en) 2000-08-24
NO20013964L (no) 2001-10-15
ID30504A (id) 2001-12-13
TR200102385T2 (tr) 2002-09-23
IL192666A0 (en) 2009-02-11
CN1339963A (zh) 2002-03-13
GB9903547D0 (en) 1999-04-07
AR082579A2 (es) 2012-12-19
KR20080064914A (ko) 2008-07-09
HUP0105364A3 (en) 2003-02-28
PL350556A1 (en) 2002-12-16
DK1152750T3 (da) 2009-08-24
PE20001499A1 (es) 2001-01-12

Similar Documents

Publication Publication Date Title
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
BR9916857A (pt) 4 heteroaril diarilaminas
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
TR200100054T2 (tr) Paroksetin metansülfonat
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
TR200002299T2 (tr) Epotilon kompozisyonları.
HUP0301722A3 (en) Pyrimidine derivatives, pharmaceutical compositions containing them and their use
HUP0400708A3 (en) Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DE69716135T2 (de) In 6-position durch thio substituierte paclitaxele
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
TR200200795T2 (tr) 5-HT1B antagonistleri olarak piperazin türevleri
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
PL346764A1 (en) New oral formulation for 5-ht4
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
IS2258B (is) Setin tríasóló-pýridasín afleiða, lyfjasamsetningar gerðar úr henni
SE9802937D0 (sv) Novel compounds
BR0208566B1 (pt) Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
DE60134414D1 (de) 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DA INT. CL: A61K 9/107; A61K 31/553; A61K 9/107; A61K 31/553; A61K 47/10; A61K 47/34; A61K 47/44; A61P 9/00; A61P 9/10; A61P 25/00; A61P 29/00; A61P 31/00; A61P 35/00; A61P 43,00.

Ipc: A61K 9/107 (2009.01), A61K 31/553 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/02/2020